Department of Tissue Pathology, ICPMR, Westmead Hospital, Wentworthville, New South Wales, Australia.
Pathology. 2012 Jan;44(1):1-6. doi: 10.1097/PAT.0b013e32834d7bd8.
Human papillomavirus (HPV) is a highly transmissible infection responsible for a range of diseases in women including cervical carcinomas, vulval carcinomas, anogenital carcinomas and genital warts. In men it is associated with penile carcinomas, anogenital carcinomas and oropharyngeal carcinomas. The history of the development of HPV vaccines includes a significant Australian input and represents a tremendous advancement in our understanding of HPV virology as well as further elucidating the overall contribution of viruses to carcinogenesis. Prophylactic HPV vaccines were licensed for use in Australia in 2007 in order to protect against development of future cases of cervical carcinoma and early results are promising. The benefit of the vaccine will not be restricted to cervical lesions and cross protection amongst a variety of HPV subtypes is described. The development of the HPV vaccine and its ultimate incorporation into our National Immunisation Schedule is reviewed.
人乳头瘤病毒（HPV）是一种高度传染性的感染，可导致女性罹患多种疾病，包括宫颈癌、外阴癌、肛门生殖器癌和生殖器疣。在男性中，它与阴茎癌、肛门生殖器癌和口咽癌有关。HPV 疫苗的发展历史包括澳大利亚的重要贡献，这代表着我们对 HPV 病毒学的理解有了巨大的进步，进一步阐明了病毒对癌症发生的整体贡献。为了预防未来宫颈癌病例的发生，HPV 预防性疫苗于 2007 年在澳大利亚获得许可使用，早期结果令人鼓舞。疫苗的益处不仅局限于宫颈病变，而且还描述了多种 HPV 亚型之间的交叉保护。本文回顾了 HPV 疫苗的发展及其最终纳入国家免疫计划的情况。
